Stock fact sheet · data as of
Skye Bioscience, Inc. (SKYE): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is SKYE undervalued?
At 1.57 (close of 16 Oct 2026), SKYE trades 100% over the GLS average fair value of 0.7856, with 0 of 1 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
Only 1 of the nine models produced a value (DCF); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.
The nightly engine files SKYE under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for SKYE
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 0.7856 | -50% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 4.28 | +173% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 12.00 | +664% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: SKYE passes 1 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 0.5 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -275.5%, ROE -279.3%, ROA -197.5% - with debt at 0.01 times equity and negative free cash flow.
Skye Bioscience, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 5/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 1 / 9 | ROIC | -275.5% |
|---|---|---|---|
| GLS Moat | 0.5 / 10 | ROE | -279.3% |
| Debt / equity | 0.01 | ROA | -197.5% |
| Free-cash-flow yield | -562.7% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 3: Weak
SKYE scores 3 out of 100 on the Wheel Score, in the Weak band (under 50). Value 0/25, Health 2/20, Moat 1/15, Premium 0/20, Stability 0/20. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.
No implied volatility is recorded for SKYE - the nightly snapshot found no near-the-money contracts 20-60 days out - so the Premium part of the Wheel Score is zero. Chain open interest is 3,296 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 37k shares a day on a market cap of $7M, with a beta of 2.86 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 0 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -100% margin of safety | |
| Health | 2 / 20 | Piotroski 1/9 | |
| Moat | 1 / 15 | moat 0.5/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 0 / 20 | 37k shares/day, $7M cap, beta 2.86 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 9 Nov 2026, 24 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Skye Bioscience, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| AIM AIM ImmunoTech Inc. | 0.1703 | - | - | 31No options | $7M |
| ZEOX Zeo ScientifiX, Inc. | 0.9000 | - | - | 31No options | $7M |
| AIMD Ainos, Inc. | 0.9600 | - | - | 19No options | $7M |
| FBLG FibroBiologics, Inc. Common Stock | 1.00 | 0.7260 | -38% | 14No options | $7M |
| IMRN Immuron Limited | 1.03 | - | - | 30No options | $7M |
| APUS Apimeds Pharmaceuticals US, Inc | 4.39 | - | - | 23No options | $7M |
| ACXP Acurx Pharmaceuticals, Inc. | 1.17 | 5.07 | +77% | 38No options | $7M |
| CUBT Curative Biotechnology, Inc. | 0.9500 | - | - | 24No options | $6M |
| SNGX Soligenix, Inc. | 0.3407 | 1.27 | +73% | 35No options | $7M |
| SNTI Senti Biosciences, Inc. | 0.2408 | - | - | 23No options | $7M |
| CNSP CNS Pharmaceuticals, Inc. | 5.18 | 7.71 | +33% | 35No options | $8M |
| CURX Curanex Pharmaceuticals Inc Common Stock | 4.83 | 3.26 | -48% | 13No options | $8M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about SKYE
Is SKYE undervalued right now?
No: at 1.57 the stock trades 100% above the GLS average fair value of 0.7856 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of SKYE and what does it mean?
SKYE scores 3 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for SKYE?
0.7856 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Skye Bioscience, Inc. report earnings next?
The next earnings report is due on 9 Nov 2026, 24 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does SKYE have listed options, and how liquid are they?
Yes. The nightly snapshot found 18 listed contracts with 3,296 open interest across all expiries. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.